allograft

(redirected from allograft rejection)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

allograft:

see transplantation, medicaltransplantation, medical,
surgical procedure by which a tissue or organ is removed and replaced by a corresponding part, usually from another part of the body or from another individual.
..... Click the link for more information.
.

allograft

[′a·lō‚graft]
(biology)
Graft from a donor transplanted to a genetically dissimilar recipient of the same species. Also known as allogeneic graft.
References in periodicals archive ?
Obliterative bronchiolitis, also known as bronchiolitis obliterans or OB, is a direct manifestation of chronic or acute allograft rejection.
This contrasts with the authors' existing knowledge that C4d deposition along the peritubular capillaries is a fairly specific marker of Immorally mediated allograft rejection.
Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.
Chart reviews were performed by investigators blinded to the results of donor DNA measurement to ascertain each patient's posttransplantation course to identify episodes of kidney or pancreas allograft rejection as determined by standardized histologic grading of biopsies.
Tacrolimus has become an established immunosuppressive agent for the prophylaxis and treatment of renal allograft rejection.
Chapters address topics such as chemokine receptors and transplantation, measurement of intracellular cytokines to improve therapeutic monitoring of immunosuppressive drugs following lung transplantation, polyoma BK virus nephropathy in renal transplant recipients, immunobiology of xenograft rejection, and the role of viruses in allograft rejection.
Recent data from the Lung Allograft Rejection Gene expression Observational (LARGO) study provides compelling evidence that profiling gene expression in peripheral blood can detect organ rejection in lung transplant patients.
Tacrolimus (FK 506) is a potent macrolide immunosuppressive agent that has been used as a primary immunosuppressant for the prevention of allograft rejection (1, 2).
Comparison of histopathology in acute allograft rejection and recurrent hepatitis C infection after liver transplantation.
antigen presenting cells) to block the second signal necessary to activate T cells, which are the predominate immune mediators of allograft rejection.
The European Commission approved Advagraf(R) on April 23, 2007 for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and for the treatment of allograft rejection resistant to treatment with other immunosuppressive drugs in adult patients in Europe.